Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the effects of oral Tolvaptan vs. placebo
as an adjunct to fixed dose IV furosemide on dyspnea relief in patients with acute
decompensated heart failure
The primary hypothesis is that the addition of oral Tolvaptan to fixed dose furosemide will
be more effective at relieving dyspnea than fixed dose furosemide alone